市场调查报告书
商品编码
1535214
ALK检验市场:各市场区隔规模,占有率,法律规章,偿付,2033年为止的预测ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
间变性淋巴瘤受体酪胺酸激?(ALK)基因检测用于检测非小细胞肺癌肿瘤细胞内的基因重排,其结果可用于治疗非小细胞肺癌(NSCLC)可能带来治疗方法为了
ALK 是受体酪胺酸激?家族的成员,是控制细胞增生和分化的关键因子。大多数 ALK 基因突变都是易位,即 ALK 基因与其他基因结合形成融合癌基因。 ALK 基因检测用于检测非小细胞肺癌肿瘤细胞内的基因重排,其结果可指导非小细胞肺癌 (NSCLC) 的治疗。
本报告提供全球ALK检验市场相关资料详细考察,提供市场上竞争情形,SWOT分析,到2033年为止的市场预测,地区,各国的趋势等资讯。
ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells; the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC).
ALK is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation and differentiation. The majority of ALK mutations are translocations, whereby the ALK gene is partnered with other gene to form a fusion oncogene. ALK gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells, the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC).
Each of the covered 39 countries color-coded and fully-sourced market model is equipped with epidemiology-based indications. The interactive excel deliverable covers value, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed ALK Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Integrated DNA Technologies Inc, Biocare Medical LLC, Thermo Fisher Scientific Inc, Cancer Diagnostics, Inc., Abbott Laboratories, Sysmex Corp, ZytoVision GmbH, Qiagen NV, Bio-Rad Laboratories Inc, Illumina Inc, New England Biolabs Inc, EntroGen, Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -